Trial Profile
A Phase I Dose Escalation Study of LBH589 [panobinostat] in Combination With Imatinib Mesylate for Treatment of Patients With Chronic Myeloid Leukemia in Cytogenetic Remission With Residual BCR-ABL +Cells Detectably by Q-PCR [quantitative-polymerase chain reaction].
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Panobinostat (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Biomarker
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jul 2012 Planned number of patients changed from 18 to 23 as reported by ClinicalTrials.gov.
- 26 Mar 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.